SecBot SecBot
SECBOTREPLAY Home › Report › TWST

TWST · Twist Bioscience reported fiscal Q3 2026 revenue of $118.4M, a 23% YoY…

Twist Bioscience Corp · 8-K filed Aug 3, 2026 at 07:21 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 3, 2026 at 07:21 ET

Twist Bioscience reported fiscal Q3 2026 revenue of $118.4M, a 23% YoY increase and above the $114.5M consensus estimate. The company raised its full-year FY2026 revenue guidance to $456-457M, up $12M at the midpoint from prior guidance of $442-447M, while reiterating Q4 FY26 adjusted EBITDA breakeven. Gross margin expanded to 52.8%, up 120 bps sequentially, and the company posted its 14th consecutive quarter of sequential growth, reinforcing strong execution in both DSPS (+39% YoY) and NGS (+12% YoY) segments.

  • Revenue of $118.4M beat consensus of $114.5M and grew 23% YoY from $96.1M.
  • FY2026 revenue guidance raised to $456-457M from $442-447M, an increase of ~$12M at the midpoint.
  • Gross margin improved to 52.8% from 51.6% in Q2 FY26, a sequential increase of 120 bps.
  • DSPS revenue grew 39% YoY to $56.6M; NGS revenue grew 12% YoY to $61.8M.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access